Aug 08, 2022 / 12:00PM GMT
Operator
Welcome to the BioNTech Second Quarter 2022 Update Call. I would like to hand the call over to the Vice President of Investor Relations and Strategy, Sylke Maas. Please go ahead, Sylke.
Sylke Maas - BioNTech SE - VP of IR and Business Strategy
Good morning and good afternoon. Thank you for joining us today to review BioNTech's second quarter '22 clinical and operational progress and financial results. A few housekeeping items before we start. I invite you to view the slides that accompany the webcast and the second quarter 2022 press release, both of which were issued this morning and can be found in the Investors section of our website.
As outlined on Slide 2, during today's presentation, we will be making several forward-looking statements. These forward-looking statements include, but are not limited to, our current COVID-19 vaccine revenues, as these include figures that are derived from the preliminary estimates provided by our partners; our estimated financial results for 2022; the continued global demand for our COVID-19 vaccine; our target
Q2 2022 BioNTech SE Earnings Call Transcript
Aug 08, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers